Mizuho Maintains Outperform on NeuroPace, Lowers Price Target to $12
Mizuho analyst Anthony Petrone maintains NeuroPace (NASDAQ:NPCE) with a Outperform and lowers the price target from $22 to $12.
Follow the latest Neuropace, Inc. (NPCE) news and market headlines alongside the live NPCE price. Stay informed on what's moving NPCE.
Mizuho analyst Anthony Petrone maintains NeuroPace (NASDAQ:NPCE) with a Outperform and lowers the price target from $22 to $12.
HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and lowers the price target from $20 to $12.
Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came out today. SBC
Keybanc analyst Brett Fishbin maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $18 to $14.
Leerink Partners analyst Mike Kratky downgrades NeuroPace (NASDAQ:NPCE) from Outperform to Market Perform and announces $7 price target.
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report
NeuroPace shares tumble after-hours after missing revenue estimates and cutting 2026 sales guidance.
NeuroPace (NPCE) reported a quarterly loss of $0.03 per share, beating consensus estimates of $0.06 loss by 50%, but missed revenue expectations with $23.1 million versus the estimated $26.9 million. The company has underperformed the S&P 500 by 30.2% year-to-date. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
NeuroPace (NASDAQ:NPCE) lowers FY2026 sales outlook from $99.500 million-$101.500 million to $91.000 million-$92.000 million vs $100.321 million estimate.
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to NPCE, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.